Skip to main content
Clinical Trials/NCT04281693
NCT04281693UnknownNot Applicable

Identification of a New Screening Strategy for 2019 Novel Coronavirus Infection

Affiliated Hospital to Academy of Military Medical Sciences1 site in 1 country230 target enrollmentStarted: February 1, 2020Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
230
Locations
1
Primary Endpoint
Screening accuracy

Study Overview

Brief Summary

Since Dec 2019, over 70000 novel coronavirus infection pneumonia (NCIP) patients were confirmed. 2019 novel coronavirus (2019 nCoV) is a RNA virus, which spread mainly from person-to-person contact. Most of the symptoms are non-specific, including fever, fatigue, dry cough. Sever NCIP patients may have shortness of breath and dyspnea, and progress to acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS). The mortality is reported to be around 2.3%. Thus, early detection and early treatment is very important to the improvement of NCIP patients' prognosis. At present, NCIP RNA detection of pharyngeal swab specimen by RT-PCR is recommended. However, due to the universal susceptibility to 2019 nCoV in general population and limited number of NCIP RNA detection kits available, to identify an efficient screening strategy is urgently needed. This study aim to develop and validate the diagnostic accuracy and screening efficiency of a new NCIP screening strategy, which can benefit the disease prevention and control.

Detailed Description

This clinical trial is designed to compare the screen accuracy and efficiency of two screening strategies. Considering that the general population is susceptible to 2019 nCoV, a great number of people need to be screened for NCIP. The new screening strategy of minipool testing may not only obtain a comparable accuracy to the standard individual testing, but also save time and money, which may benefit the current clinical practice.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Screening
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Who agree to participate in the study and sign written informed consent

Exclusion Criteria

  • •Confirmed NCIP patients

Arms & Interventions

Screening participants

Experimental

Intervention: Standard screening strategy (Diagnostic Test)

Screening participants

Experimental

Intervention: New screening strategy (Diagnostic Test)

Outcomes

Primary Outcomes

Screening accuracy

Time Frame: 1 month

The screening accuracy of the two screening strategies were calculated and compared.

Secondary Outcomes

  • Cost-effectiveness analysis(1 month)

Investigators

Sponsor
Affiliated Hospital to Academy of Military Medical Sciences
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

A New Screening Strategy for 2019 Novel... | Clinical Trial